Iproniazid

Identification

Name
Iproniazid
Accession Number
DB04818
Type
Small Molecule
Groups
Withdrawn
Description

Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Euphozid / Iprazid / Ipronid (A.F.I.) / Ipronin / Marsilid (Genopharm) / Rivivol (Zambeletti)
Categories
UNII
D892HFI3XA
CAS number
54-92-2
Weight
Average: 179.219
Monoisotopic: 179.105862053
Chemical Formula
C9H13N3O
InChI Key
NYMGNSNKLVNMIA-UHFFFAOYSA-N
InChI
InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)
IUPAC Name
N'-(propan-2-yl)pyridine-4-carbohydrazide
SMILES
CC(C)NNC(=O)C1=CC=NC=C1

Pharmacology

Indication

For the treatment of depression (originally intended to treat tuberculosis).

Structured Indications
Not Available
Pharmacodynamics

Iproniazid is a monoamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant.

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineIproniazid may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineIproniazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineIproniazid may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineIproniazid may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcarboseIproniazid may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololIproniazid may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Iproniazid.Experimental
AlbiglutideIproniazid may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Iproniazid.Approved, Illicit
AliskirenIproniazid may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Iproniazid.Approved, Investigational
AlogliptinIproniazid may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Iproniazid.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Iproniazid.Illicit
AlprenololIproniazid may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Iproniazid.Approved
AmbrisentanIproniazid may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineIproniazid may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineIproniazid may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineIproniazid may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Amoxapine.Approved
AmphetamineIproniazid may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Iproniazid.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Arformoterol.Approved, Investigational
AtenololIproniazid may increase the hypotensive activities of Atenolol.Approved
AtomoxetineIproniazid may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineIproniazid may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Bambuterol.Approved, Investigational
BenazeprilIproniazid may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideIproniazid may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinIproniazid may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetamineIproniazid may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilIproniazid may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Iproniazid.Approved
BetaxololIproniazid may increase the hypotensive activities of Betaxolol.Approved
BethanidineIproniazid may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Iproniazid is combined with Bezafibrate.Approved
BietaserpineIproniazid may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostIproniazid may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololIproniazid may increase the hypotensive activities of Bisoprolol.Approved
BosentanIproniazid may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Iproniazid may increase the hypotensive activities of BQ-123.Investigational
BretyliumIproniazid may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Brimonidine.Approved
BrofaromineIproniazid may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineIproniazid may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BupranololIproniazid may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproniazid.Approved, Illicit, Investigational, Vet Approved
BupropionIproniazid may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Iproniazid.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iproniazid.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Iproniazid.Approved
CadralazineIproniazid may increase the hypotensive activities of Cadralazine.Experimental
CafedrineIproniazid may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinIproniazid may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanIproniazid may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilIproniazid may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilIproniazid may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilIproniazid may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iproniazid.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Iproniazid.Illicit, Investigational, Vet Approved
CaroxazoneIproniazid may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololIproniazid may increase the hypotensive activities of Carteolol.Approved
CarvedilolIproniazid may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololIproniazid may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideIproniazid may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineIproniazid may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideIproniazid may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneIproniazid may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineIproniazid may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilIproniazid may increase the hypotensive activities of Cilazapril.Approved
CirazolineIproniazid may increase the hypertensive activities of Cirazoline.Experimental
CitalopramIproniazid may increase the serotonergic activities of Citalopram.Approved
ClemastineIproniazid may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineIproniazid may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineIproniazid may increase the hypotensive activities of Clonidine.Approved
CloranololIproniazid may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Iproniazid.Approved, Illicit
CryptenamineIproniazid may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Iproniazid.Approved
CyclopenthiazideIproniazid may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideIproniazid may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineIproniazid may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinIproniazid may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineIproniazid may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinIproniazid may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilIproniazid may increase the hypotensive activities of Delapril.Experimental
DeserpidineIproniazid may increase the hypotensive activities of Deserpidine.Approved
DesipramineIproniazid may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineIproniazid may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidateIproniazid may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineIproniazid may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanIproniazid may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Iproniazid.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Iproniazid.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Iproniazid.Approved, Investigational
DiazoxideIproniazid may increase the hypotensive activities of Diazoxide.Approved
DibenzepinIproniazid may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorspermineIproniazid may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionIproniazid may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineIproniazid may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iproniazid.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Iproniazid.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Iproniazid.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iproniazid.Experimental, Illicit
DiltiazemIproniazid may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iproniazid.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Iproniazid is combined with Dipivefrin.Approved
DisopyramideIproniazid may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideIproniazid may increase the hypotensive activities of Dorzolamide.Approved
DosulepinIproniazid may increase the serotonergic activities of Dosulepin.Approved
DoxapramIproniazid may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinIproniazid may increase the hypotensive activities of Doxazosin.Approved
DoxepinIproniazid may increase the serotonergic activities of Doxepin.Approved
DoxylamineIproniazid may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Iproniazid.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Iproniazid.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Iproniazid is combined with Droxidopa.Approved, Investigational
DulaglutideIproniazid may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineIproniazid may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Iproniazid.Experimental, Illicit
EfonidipineIproniazid may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Iproniazid.Approved, Investigational
EmpagliflozinIproniazid may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilIproniazid may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatIproniazid may increase the hypotensive activities of Enalaprilat.Approved
EndralazineIproniazid may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Iproniazid.Approved, Investigational
EpanololIproniazid may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Iproniazid is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineIproniazid may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolIproniazid may increase the hypotensive activities of Epoprostenol.Approved
EprosartanIproniazid may increase the hypotensive activities of Eprosartan.Approved
ErgotamineIproniazid may increase the hypertensive activities of Ergotamine.Approved
EscitalopramIproniazid may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineIproniazid may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Iproniazid.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Iproniazid.Approved, Illicit
EtoperidoneIproniazid may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Iproniazid.Illicit, Vet Approved
ExenatideIproniazid may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineIproniazid may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamIproniazid may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Fenoterol.Approved, Investigational
FentanylFentanyl may increase the serotonergic activities of Iproniazid.Approved, Illicit, Investigational, Vet Approved
Ferulic acidIproniazid may increase the hypotensive activities of Ferulic acid.Experimental
FluoxetineIproniazid may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineIproniazid may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Formoterol.Approved, Investigational
FosinoprilIproniazid may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Iproniazid.Approved, Investigational
FurazolidoneIproniazid may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Iproniazid.Experimental
GliclazideIproniazid may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideIproniazid may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideIproniazid may increase the hypoglycemic activities of Glipizide.Approved
GlyburideIproniazid may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzIproniazid may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelIproniazid may increase the hypotensive activities of Guanadrel.Approved
GuanazodineIproniazid may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineIproniazid may increase the hypotensive activities of Guanethidine.Approved
GuanfacineIproniazid may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorIproniazid may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzIproniazid may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanIproniazid may increase the hypotensive activities of Guanoxan.Experimental
HarmalineIproniazid may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Iproniazid.Approved, Illicit, Investigational
HexamethoniumIproniazid may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineIproniazid may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineIproniazid may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideIproniazid may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideIproniazid may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineIproniazid may increase the hypertensive activities of Hydroxyamphetamine.Approved
ImidaprilIproniazid may increase the hypotensive activities of Imidapril.Investigational
ImipramineIproniazid may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Indacaterol.Approved
IndalpineIproniazid may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIproniazid may increase the hypotensive activities of Indapamide.Approved
IndenololIproniazid may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIproniazid may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartIproniazid may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirIproniazid may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineIproniazid may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineIproniazid may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanIproniazid may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproIproniazid may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Iproniazid.Approved
IprindoleIproniazid may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproniazid may increase the hypertensive activities of Iproclozide.Withdrawn
IrbesartanIproniazid may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Iproniazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isoprenaline.Approved
IsradipineIproniazid may increase the hypotensive activities of Isradipine.Approved
KetanserinIproniazid may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Iproniazid.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Iproniazid.Approved, Nutraceutical, Withdrawn
LabetalolIproniazid may increase the hypotensive activities of Labetalol.Approved
LacidipineIproniazid may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostIproniazid may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineIproniazid may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Iproniazid.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Iproniazid.Approved, Investigational
LevomilnacipranIproniazid may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinIproniazid may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iproniazid.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Linezolid.Approved, Investigational
LinsidomineIproniazid may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideIproniazid may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineIproniazid may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilIproniazid may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Iproniazid.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Iproniazid is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Iproniazid.Illicit
LofepramineIproniazid may increase the serotonergic activities of Lofepramine.Experimental
LofexidineIproniazid may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanIproniazid may increase the hypotensive activities of Losartan.Approved
MacitentanIproniazid may increase the hypotensive activities of Macitentan.Approved
ManidipineIproniazid may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iproniazid.Approved
MebanazineIproniazid may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineIproniazid may increase the hypotensive activities of Mecamylamine.Approved
MecaserminIproniazid may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneIproniazid may increase the hypertensive activities of Mephedrone.Investigational
MephentermineIproniazid may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Iproniazid.Experimental
MequitazineIproniazid may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolIproniazid may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminIproniazid may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Iproniazid.Approved, Illicit
MethamphetamineIproniazid may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidineIproniazid may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineIproniazid may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Iproniazid.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Iproniazid.Experimental
Methylene blueIproniazid may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateIproniazid may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololIproniazid may increase the hypotensive activities of Metipranolol.Approved
MetolazoneIproniazid may increase the hypotensive activities of Metolazone.Approved
MetoprololIproniazid may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineIproniazid may increase the hypotensive activities of Metyrosine.Approved
MianserinIproniazid may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilIproniazid may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineIproniazid may increase the hypertensive activities of Midodrine.Approved
MidomafetamineIproniazid may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneIproniazid may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolIproniazid may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranIproniazid may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Iproniazid.Approved
MinoxidilIproniazid may increase the hypotensive activities of Minoxidil.Approved
MirtazapineIproniazid may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAIproniazid may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Iproniazid is combined with Moclobemide.Approved
MoexiprilIproniazid may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Morphine.Approved, Investigational
MoxonidineIproniazid may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineIproniazid may increase the hypotensive activities of Muzolimine.Experimental
NadololIproniazid may increase the hypotensive activities of Nadolol.Approved
NaftopidilIproniazid may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iproniazid.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Iproniazid.Approved, Investigational
NateglinideIproniazid may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololIproniazid may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneIproniazid may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Iproniazid.Withdrawn
NicardipineIproniazid may increase the hypotensive activities of Nicardipine.Approved
NicorandilIproniazid may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineIproniazid may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineIproniazid may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineIproniazid may increase the hypotensive activities of Nimodipine.Approved
NisoldipineIproniazid may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineIproniazid may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideIproniazid may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineIproniazid may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Iproniazid.Approved, Illicit
NortriptylineIproniazid may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinIproniazid may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Olanzapine.Approved, Investigational
OlmesartanIproniazid may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Olodaterol.Approved
OmapatrilatIproniazid may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolIproniazid may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Iproniazid.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Orciprenaline.Approved
OxprenololIproniazid may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproniazid.Approved, Investigational, Vet Approved
PargylineIproniazid may increase the hypotensive activities of Pargyline.Approved
ParoxetineIproniazid may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololIproniazid may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineIproniazid may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iproniazid.Approved, Vet Approved
PentoliniumIproniazid may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Iproniazid.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilIproniazid may increase the hypotensive activities of Perindopril.Approved
PethidineIproniazid may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Iproniazid.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Iproniazid.Approved
PheniprazineIproniazid may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Iproniazid.Experimental
PhenoxybenzamineIproniazid may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineIproniazid may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineIproniazid may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineIproniazid may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineIproniazid may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Iproniazid.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Iproniazid.Investigational
PinacidilIproniazid may increase the hypotensive activities of Pinacidil.Withdrawn
PindololIproniazid may increase the hypotensive activities of Pindolol.Approved
PioglitazoneIproniazid may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Iproniazid.Investigational
PirlindolePirlindole may increase the hypertensive activities of Iproniazid.Approved
PivhydrazineIproniazid may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenIproniazid may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorIproniazid may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideIproniazid may increase the hypotensive activities of Polythiazide.Approved
PramlintideIproniazid may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinIproniazid may increase the hypotensive activities of Prazosin.Approved
ProcarbazineIproniazid may increase the hypertensive activities of Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Procaterol.Approved, Investigational
PropranololIproniazid may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineIproniazid may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Iproniazid.Investigational
PseudoephedrineIproniazid may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilIproniazid may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineIproniazid may increase the hypoglycemic activities of Quinine.Approved
RamiprilIproniazid may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Iproniazid.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Iproniazid.Approved
RemikirenIproniazid may increase the hypotensive activities of Remikiren.Approved
RepaglinideIproniazid may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineIproniazid may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Reserpine.Approved, Investigational
RilmenidineIproniazid may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatIproniazid may increase the hypotensive activities of Riociguat.Approved
RitobegronIproniazid may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Ritodrine.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Iproniazid.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Iproniazid.Approved, Investigational
RosiglitazoneIproniazid may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineIproniazid may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salmeterol.Approved
SaprisartanIproniazid may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinIproniazid may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Iproniazid.Approved, Investigational, Vet Approved
SelexipagIproniazid may increase the hypotensive activities of Selexipag.Approved
SertralineIproniazid may increase the serotonergic activities of Sertraline.Approved
SitagliptinIproniazid may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanIproniazid may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilIproniazid may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Iproniazid.Approved, Investigational
SulfadiazineIproniazid may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleIproniazid may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleIproniazid may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Iproniazid.Approved, Investigational
SunitinibIproniazid may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololIproniazid may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Iproniazid.Approved
TelmisartanIproniazid may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilIproniazid may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Terbutaline.Approved
TerlipressinIproniazid may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Iproniazid.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iproniazid.Approved
TetrahydropalmatineIproniazid may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineIproniazid may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineIproniazid may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Iproniazid.Approved, Investigational
TiboloneIproniazid may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenIproniazid may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Iproniazid.Experimental
TimololIproniazid may increase the hypotensive activities of Timolol.Approved
TolazamideIproniazid may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineIproniazid may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideIproniazid may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproniazid.Approved, Withdrawn
TolonidineIproniazid may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Iproniazid.Approved
TorasemideIproniazid may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Iproniazid.Approved, Investigational
TrandolaprilIproniazid may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineIproniazid may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Iproniazid.Approved
TravoprostIproniazid may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Trazodone.Approved, Investigational
TreprostinilIproniazid may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideIproniazid may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinIproniazid may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanIproniazid may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineIproniazid may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneIproniazid may increase the hypotensive activities of Unoprostone.Approved
UrapidilIproniazid may increase the hypotensive activities of Urapidil.Investigational
ValsartanIproniazid may increase the hypotensive activities of Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Iproniazid.Approved
VenlafaxineIproniazid may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Iproniazid.Approved
VincamineIproniazid may increase the hypotensive activities of Vincamine.Experimental
VinpocetineIproniazid may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Iproniazid.Approved
XipamideIproniazid may increase the hypotensive activities of Xipamide.Experimental
XylometazolineIproniazid may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineIproniazid may increase the serotonergic activities of Zimelidine.Withdrawn
ZofenoprilIproniazid may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Iproniazid.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,685,585.

General References
Not Available
External Links
KEGG Drug
D02579
KEGG Compound
C11777
PubChem Compound
3748
PubChem Substance
46505059
ChemSpider
3617
BindingDB
29136
ChEBI
5958
ChEMBL
CHEMBL92401
Wikipedia
Iproniazid

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)161-161.5U.S. Patent 2,685,585.
logP0.37HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.674 mg/mLALOGPS
logP0.02ALOGPS
logP0.31ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)13.66ChemAxon
pKa (Strongest Basic)3.82ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area54.02 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity60.96 m3·mol-1ChemAxon
Polarizability19.19 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9929
Blood Brain Barrier+0.9799
Caco-2 permeable+0.6657
P-glycoprotein substrateNon-substrate0.7484
P-glycoprotein inhibitor INon-inhibitor0.9191
P-glycoprotein inhibitor IINon-inhibitor0.9932
Renal organic cation transporterNon-inhibitor0.9166
CYP450 2C9 substrateNon-substrate0.8608
CYP450 2D6 substrateNon-substrate0.873
CYP450 3A4 substrateNon-substrate0.614
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9316
CYP450 2D6 inhibitorNon-inhibitor0.9522
CYP450 2C19 inhibitorNon-inhibitor0.9293
CYP450 3A4 inhibitorNon-inhibitor0.7165
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9221
Ames testNon AMES toxic0.5653
CarcinogenicityNon-carcinogens0.7081
BiodegradationNot ready biodegradable0.9893
Rat acute toxicity2.6600 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.943
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinecarboxylic acids and derivatives
Direct Parent
Pyridinecarboxylic acids and derivatives
Alternative Parents
Heteroaromatic compounds / Carboxylic acid hydrazides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Pyridine carboxylic acid or derivatives / Heteroaromatic compound / Carboxylic acid hydrazide / Azacycle / Carboxylic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
carbohydrazide, pyridines (CHEBI:5958) / a small molecule (IPRONIAZID)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da

Drug created on September 11, 2007 14:12 / Updated on December 01, 2017 15:33